EYU688

Small molecule

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Dengue
NCT06006559 · Novartis Pharmaceuticals
2024-02-20 – 2027-07-30 · Dengue
What this study did

Competitive landscape

This drug's own stage for Dengue: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
EYU688: this drugPhase 2Small moleculeDengue NS4Bnot yet gradedNo reviewed efficacy summary in this indication
V181Phase 3Vaccine—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow EYU688 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
July 2027 (1)
Phase 2DengueRecruiting
Est. primary completion 2027-07-22 · NCT06006559 · CT.gov ↗
What to watch

See the full readout calendar ↗